Search results
Showing 661 to 675 of 811 results for adult social
effective in improving dietary habits affecting the oral health of children and adults, and in particular those at high risk of poor...
improving oral health and reducing oral health inequalities among groups of adults at high risk of poor oral health? Any explanatory...
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
NG98/3 Question Use of hearing aids and incidence of dementia:- In adults with hearing loss, does the use of hearing aids reduce the...
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)
Evidence-based recommendations on lorlatinib (Lorviqua) for untreated ALK-positive advanced non-small-cell lung cancer in adults.
interventions for depression and anxiety disorders in adults with mild to moderate learning disabilities:- For adults with...
Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)
Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)
Evidence-based recommendations on necitumumab (Portrazza) for treating locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small-cell lung cancer in adults who have not had chemotherapy.
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating PD-L1-positive non-small-cell lung cancer in adults who have had chemotherapy.
Tocilizumab for the treatment of rheumatoid arthritis (TA247)
Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis in adults.
Eltrombopag for treating chronic immune thrombocytopenia (TA293)
Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune thrombocytopenia in adults.
Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults.
Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems)
Dupilumab for treating moderate to severe prurigo nodularis (TA955)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.